Related Experiment Video

Updated: Aug 30, 2026

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
10:35

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

Inflammation as a therapeutic target: a unique role for abciximab

Dean J Kereiakes1

  • 1Ohio State University, The Lindner Center for Research and Education, and The Ohio Heart Health Center, Cincinnati, Ohio 45219, USA. lindner@fuse.net

American Heart Journal
|October 18, 2003
PubMed

Insights

Vascular inflammation drives adverse outcomes in cardiovascular disease and diabetes. Abciximab demonstrates anti-inflammatory effects, potentially improving plaque stability and patient prognosis.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Pharmacology

Background:

  • Vascular inflammation is a key factor in acute coronary syndromes and post-percutaneous coronary intervention injury.
  • Increased vascular inflammation is linked to poor clinical outcomes like death, myocardial infarction, and restenosis.
  • Patients with diabetes mellitus exhibit heightened vascular inflammation.

Purpose of the Study:

  • To present data on the anti-inflammatory effects of abciximab.
  • To discuss how these effects may influence atherosclerotic plaque stability.
  • To explore the role of abciximab's anti-inflammatory properties in modulating late clinical outcomes.

Main Methods:

  • Review of existing data on abciximab's pharmacological actions.
  • Analysis of studies correlating vascular inflammation with clinical outcomes.
  • Discussion of potential mechanisms linking anti-inflammatory effects to plaque stabilization.

Main Results:

  • Adjunctive therapies, including abciximab, possess anti-inflammatory properties beyond their primary mechanisms.
  • Abciximab exhibits demonstrable anti-inflammatory effects.
  • These effects may contribute to improved atherosclerotic plaque stability.

Conclusions:

  • Vascular inflammation is a critical therapeutic target in cardiovascular disease.
  • Abciximab's anti-inflammatory actions may offer significant clinical benefits.
  • Targeting vascular inflammation represents a promising strategy for managing cardiovascular events.

More Related Videos

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammation01:38

Inflammation

Overview